Connor Clark & Lunn Investment Management Ltd. Has $2.22 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 132.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 138,605 shares of the company’s stock after acquiring an additional 78,953 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Entrada Therapeutics were worth $2,215,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TRDA. US Bancorp DE acquired a new stake in shares of Entrada Therapeutics in the 3rd quarter valued at about $42,000. Acadian Asset Management LLC acquired a new stake in Entrada Therapeutics in the 1st quarter valued at approximately $79,000. SG Americas Securities LLC bought a new stake in Entrada Therapeutics in the 3rd quarter valued at approximately $156,000. Allspring Global Investments Holdings LLC boosted its position in Entrada Therapeutics by 87.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 27,631 shares of the company’s stock worth $394,000 after acquiring an additional 12,868 shares during the last quarter. Finally, BayBridge Capital Group LLC bought a new position in shares of Entrada Therapeutics during the 3rd quarter worth approximately $464,000. 86.39% of the stock is owned by institutional investors.

Insider Activity at Entrada Therapeutics

In other Entrada Therapeutics news, COO Nathan J. Dowden sold 1,904 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.07, for a total value of $28,693.28. Following the sale, the chief operating officer now owns 125,996 shares in the company, valued at $1,898,759.72. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Natarajan Sethuraman sold 2,700 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $20.04, for a total value of $54,108.00. Following the transaction, the insider now owns 160,888 shares of the company’s stock, valued at $3,224,195.52. This represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,933 shares of company stock valued at $410,816. 7.59% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Oppenheimer boosted their price objective on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright increased their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

Entrada Therapeutics Stock Up 1.3 %

NASDAQ:TRDA opened at $19.04 on Tuesday. Entrada Therapeutics, Inc. has a twelve month low of $11.05 and a twelve month high of $20.49. The firm has a market capitalization of $712.48 million, a price-to-earnings ratio of 11.82 and a beta of -0.26. The stock’s 50 day moving average price is $17.07 and its two-hundred day moving average price is $16.12.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.